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ABSTRACT
The goal of adjuvant (post-surgery) radiation therapy (RT) for breast cancer 
(BC) is to eliminate residual cancer cells, leading to better local tumor control and 
thus improving patient survival. However, radioresistance increases the risk of 
tumor recurrence and negatively affects survival. Recent evidence shows that breast 
cancer stem cells (BCSCs) are radiation-resistant and that relatively differentiated 
BC cells can be reprogrammed into induced BCSCs (iBCSCs) via radiation-induced 
re-expression of the stemness genes. Here we show that in irradiation (IR)-treated 
mice bearing syngeneic mammary tumors,  IR-induced stemness correlated with 
increased spontaneous lung metastasis (51.7%). However, IR-induced stemness was 
blocked by targeting the NF-κB- stemness gene pathway with disulfiram (DSF)and 
Copper (Cu2+). DSF is an inhibitor of aldehyde dehydrogenase (ALDH) and an FDA-
approved drug for treating alcoholism. DSF binds to Cu2+ to form DSF-Cu complexes 
(DSF/Cu), which act as a potent apoptosis inducer and an effective proteasome 
inhibitor, which, in turn, inhibits NF-κB activation. Treatment of mice with RT and 
DSF significantly inhibited mammary primary tumor growth (79.4%) and spontaneous 
lung metastasis (89.6%) compared to vehicle treated mice. This anti-tumor efficacy 
was associated with decreased stem cell properties (or stemness) in tumors. We 
expect that these results will spark clinical investigation of RT and DSF as a novel 
combinatorial treatment for breast cancer. 
INTRODUCTION
Adjuvant RT is given to the breast cancer patients 
after conservation surgery and may be given to the chest 
wall after mastectomy to achieve better local tumor control 
thus improving survival of patients [1-3]. However, 
radioresistance impedes the anti-tumor effects of RT and 
could be attributed to BCSCs, since it has recently been Oncotarget 3744 www.impactjournals.com/oncotarget
shown that BCSCs are radioresistant[4, 5]; but radiation 
also can induce BCSCs, i.e., iBCSCs from nonstem breast 
cancer cells [6]. In order to significantly improve the 
efficacy and curability of RT for breast cancer, therefore, 
novel therapeutic approaches are urgently needed to not 
only eliminate radioresisitant pre-existing BCSCs, but 
also block the formation of radiation induced new BCSCs 
from nonstem BC cells. This study is a pre-clinical effort 
to develop such a new treatment, for rapid translation into 
clinical practice, that is scientific sound, simple, safe and 
economic. 
Following  the  first  discovery  that  mature  adult 
cells can be reprogrammed to become pluripotent stem 
cells (iPSCs) by introduction of a set of four stemness 
factors (Oct4, SOX2, KLF4 and MYC) through retroviral 
transduction [7], it has been shown that cancer stem 
cells (CSCs) and relatively differentiated cancer cells 
are subject to bidirectional conversion [8]. Stemness 
gene-encoded transcription factors (TFs) play a central 
role in the determination of stem cell states [7], with 
specific transcriptional networks having essential roles 
in sustaining the growth and self-renewal of embryonic 
and neoplastic stem-like cells. The TFs Slug and SOX9 
cooperatively determine mammary stem cell states in 
both normal and malignant cells [9]. Moreover, the 
overexpression in human cancers of reprogramming TFs 
correlates with tumor progression and poor prognosis [10]. 
IR has been shown to reprogram differentiated cancer cells 
into iBCSCs or liver CSCs through the re-expression or 
upexpression of the stemness genes Oct4/SOX2/Nanog/
KLF4 and SOX2/OCT3/Oct4, respectively [6, 11]. 
There is compelling evidence showing that the 
cells expressing elevated levels of intracellular aldehyde 
dehydrogenase 1 (ALDH1) in human and mouse breast 
cancer are BCSCs [12, 13]. The ability of enhanced 
ALDH1 activity in these cells to eliminate genotoxic 
aldehydes contributes to their radio- and chemo-
resistance. Research on the CSC area has been facilitated 
by the ability to routinely detect and isolate CSCs by 
flow cytometry analysis using the ALDEFLUOR reagent 
to measure their ALDH enzymatic activity [6, 14]. 
Consequently, ALDH activity is widely used as a CSC 
marker for many malignancies including leukemia, lung, 
liver, bone, colon, pancreatic, prostate, head and neck, 
bladder, thyroid, brain, and cervical cancer and melanoma 
[15]. Moreover, we demonstrated that ALDH1A1 is not 
only a marker but also a therapeutic target for CSCs [14, 
16, 17]. 
DSF (Brand name: Antabuse) is an irreversible 
pan-ALDH inhibitor; it inhibits all the currently 
identified cytosolic and mitochondrial ALDH isoforms 
[18, 19], resulting in accumulation of, in particular, 
acetaldehyde, which causes unpleasant effects when 
alcohol is consumed. As a result, DSF has been an FDA 
approved drug for treatment of alcoholism since 1951 
[20]. Studies have shown that in cells DSF converts to 
diethyldithiocarbamate (deDTC) and that two molecules 
of deDTC bind to one molecule of copper (Cu2+) to form 
the Cu[deDTC]2 complex (DSF/Cu) [21-23]. Cu2+ is an 
essential trace element for life [24] as it plays a crucial 
role in redox reactions and generation of reactive oxygen 
species (ROS) in human cells [25, 26]. It is known that 
DSF/Cu is an effective proteasome inhibitor resulting 
in  inhibition  of  NF-κB  [21,  27].  NF-κB  is  a  key TF 
governing the activation of many genes involved in stress 
responses (e.g. IR), cell survival, apoptosis, inflammation, 
and radioresistance [28]. These NF-κB regulated stemness 
genes include ERBB2 [4], SOX9 [29], MYC [30] and 
WNT [31]. We have, therefore, investigated using human 
and mouse BC cell lines and a clinically relevant mouse 
model whether DSF/Cu can block in vitro and in vivo the 
IR-induced conversion of nonstem BC cells into iBCSCs 
via downregulation of the NF-κB-stemness gene pathway 
and enhance the efficacy of RT. 
RESULTS
DSF/Cu effectively depleted pre-existing BCSCs 
and radiation-induced BCSCs 
Based on compelling evidence showing that 
elevated ALDH activity in human and mouse BC cells is 
a marker for BCSCs and iBCSCs [6, 12-14], in this study 
we have identified these cells by flow cytometry analysis 
of BC cells as ALDHbright cells, namely those ALDH+ cells 
with twice the mean fluorescence intensity (MFI) of the 
bulk ALDH+ cell population. We detected an increased 
percentage of BCSCs in vitro following fractionated 
irradiation (3.75 Gray (Gy) /day x 5 days) of BC cell lines 
MDA-MB-231 (2.4 fold), SUM149 (1.4 fold) and UACC-
812 (4.6 fold) (Supplementary Fig. S1A). Within a range 
of doses of fractionated irradiation (1-5 Gy/day x 5 days), 
increased ALDHbright cells were detected in BC cell lines 
(Supplementary Fig. S1B). The increased percentage of 
BCSCs was caused by an increase in the absolute number 
of BCSCs accompanied by a 50.5% decrease in total 
cell number in irradiated cells vs. untreated cells, which 
indicates that IR induced the formation of new BCSCs or 
iBCSCs (Fig. 1A). The stem cell functional properties of 
these BCSCs and iBCSCs were further supported by in 
vitro formation of mammospheres (Fig. 1B) and increased 
tumorigenicity of the in vitro irradiated BC cells compared 
to untreated BC cells in mice (Fig. 1C). Treatment of cells 
with DSF/Cu effectively depleted pre-existing (before 
IR) BCSCs and iBCSCs (together referred to as BCSCs/
iBCSCs) (Fig. 1A, B, C), including those induced by IR 
from nonstem ALDHneg cells, as evidenced using this cells 
isolated  by  fluorescence-activated  cell  sorting in vitro 
(Fig. 1D). In contrast, DSF/Cu or IR and DSF/Cu did not 
exhibit toxicity on normal human mammary epithelial Oncotarget 3745 www.impactjournals.com/oncotarget
Figure 1: Depletion of BCSCs/iBCSCs by DSF/Cu as measured by decreased ALDHbright cells, mammosphere formation 
in vitro and tumorigenicity in vivo. Fraction-irradiated (3.75 Gy/day x 5 days) BC cells were cultured for 24 hours, followed by 
treatment with different agents for an additional 24 hours, as indicated. The total numbers of cell were counted using the Trypan blue 
exclusion method. The numbers of ALDHbright cells were calculated based on the total cell numbers and % of ALDHbright cells. * indicates 
P<0.05: IR or IR+DMSO or IR+Cu vs. untreated; *** indicates P<0.001: IR+DSF/Cu vs. any other treated or untreated; ΔΔΔ indicates 
P<0.001: IR+DSF vs. any other treated or untreated (A). Mammosphere formation assays were setup by seeding cells from fraction-
irradiated human BC cell lines and culturing them for 14 days. Pictures were taken and mammospheres were quantified by counting 
mammosphere numbers per well on day 14. *** indicates P<0.001: IR+DMSO or IR+Cu vs. untreated; *** indicates P<0.001: IR+ DSF/
Cu vs. any other treated or untreated except DSF/Cu; ΔΔΔ indicates P<0.001: IR+DSF vs. any other treated or untreated; *** indicates 
P<0.001: DSF/Cu vs. any other treated or untreated except IR+DSF/Cu (B). Three groups of 6 week old female NOD/SCID mice (n=4) 
were injected intraperitoneally (i.p.) with either untreated MDA-MB-231-luc cells (Untreated) or fraction-irradiated MDA-MB-231-luc 
cells and then cultured for 24 hours followed by an additional 24 hours of culture with (IR+DSF/Cu) or without (IR) treatment with DSF/
Cu. Each group was administered 2x106 cells in 25μL serum- and drug-free RPMI 1640 + 25μL Matrigel/mouse. Tumor growth was 
monitored in each mouse every 3-4 days by whole animal bioluminescent imaging (BLI) and tumor burden, quantitated as photons/second. 
Increased tumorigenicity in IR treated and lack of tumorigenicity in IR+DSF/Cu treated, compared to untreated cells, were observed. P 
values for comparison between groups are shown (C). Using diethylaminobenzaldehyde (DEAB), an inhibitor of ALDH1/3 isoforms, to 
establish the baseline fluorescence as the gating reference standard of ALDHneg population, FACS sorted MDA-MB-231 ALDHneg cells 
were fraction-irradiated and then cultured for 24 hours, followed by treatment with different agents for an additional 24 hours, as indicated 
for mammosphere formation assays. *** indicates p<0.001(D). All experiments (presented in A, B, D) were performed in duplicate and 
repeated twice, and the means ± SD are shown.Oncotarget 3746 www.impactjournals.com/oncotarget
cells as measured by cell growth and apoptosis assays 
(Supplementary Fig. S1C). 
The combination of in vitro treatment with IR 
and DSF/Cu induced more potent apoptosis of BC 
cells than either single treatment alone 
We reasoned that the depletion of BCSCs/iBCSCs by 
DSF/Cu could be due to a combination of mechanisms: 1) 
induction of apoptosis and/or 2) obstruction of conversion 
of nonstem BC cells into iBCSCs. It is known that DSF/
Cu is a potent inducer of apoptosis of BC cells through, 
at least partially, upregulation of the pro-apoptotic ROS- 
mitogen-activated protein kinases (MAPK) pathway [27]. 
We found evidence consistent with this, as p38 MAPK 
was upregulated and additionally, we found activation of 
the pro-survival AKT was inhibited in human BC UACC-
812 cells treated with a combination of IR and DSF/Cu. 
Figure 2: Inhibition by DSF/Cu of IR-induced stemness gene upregulation at the mRNA and protein levels of BC cells 
in vitro. Non-transfected BC, BC cells transfected with NF-κB p65 siRNA or control siRNA were fraction-irradiated (3.75 Gy/day x 5 
days). Non-transfected, fraction-irradiated BC cells were cultured for 24 hours, followed by treatment with different agents as indicated 
for an additional 24 hours. siRNA transfected fraction-irradiated BC cells were cultured for 24 hours, followed by treatment with NAC for 
an additional 24 hours. The expression of ERBB2, SOX9 and MYC (genes named by HUGO gene database) was analyzed by real-time 
quantitative (q) RT-PCR. Gene expression values obtained from treated cells were compared with those obtained from untreated cells, 
which were standardized to a value of 1. The results of the comparison were expressed in terms of fold change ± SD and P values are 
shown (A). Treated cells were lysed and analyzed by Western blotting for expression of HER2/Neu, SOX9 and c-myc (proteins named by 
NCBI protein database) (B). Mammosphere formation assays were performed with cells treated as indicated. Pictures were taken on day 
10 (SUM149) and on day 14 (MDA-MB-231). *** indicates P<0.001(C). The concentrations of NF-κBi and ROSi used were1 μM and 10 
mM, respectively. All of the experiments were performed in duplicate and repeated twice, and the means ± SD are shown. Oncotarget 3747 www.impactjournals.com/oncotarget
Figure 3: IR + DSF is more potent than either DSF or IR alone in targeting 4T1 tumors in mice. Mouse 4T1 cells were 
injected subcutaneously (s.c.) into the right hind leg of 28 mice. On day 7, when the tumors reached 5 mm in diameter, mice were assigned 
in a stratified randomized manner to 4 groups (n=7 per group) and the treatments were initiated. Group 1 (Vehicle control) was treated 
orally with the vehicle control olive oil. Group 2 (IR) was administered a single dose of IR (20Gy) on day 10. Group 3 (DSF) was treated 
orally with DSF once daily for 8 days. Group 4 (IR+DSF) was treated orally with DSF, once daily for 8 days and mice were administered 
a single dose of IR on day 10. Tumor sizes were monitored twice per week. Mean tumor volumes of each group ± SD and P values for 
comparison between groups are shown (A). On day 15, two mice from each group were sacrificed and their tumors (Day 15 tumors) were 
collected for analysis of intratumoral levels of stemness gene expression. Total RNA was extracted from fresh 4T1 tumors and analyzed for 
mRNA of stemness genes by quantitative real-time qRT-PCR. Gene expression values obtained from treated tumors were compared with 
those obtained from untreated tumors, which were standardized to a value of 1. The results of the comparison were expressed in terms of 
fold change. The experiments were performed in duplicate and the means of fold change ± SD and P values are shown (B). The remaining 5 
mice from each group were sacrificed on day 29 and tumors (Day 29 tumors) were collected for analysis of stemness genes using the same 
method as described above. The experiments were performed in duplicate and the means of fold change ± SD and P values are shown (C). 
Tumors from all mice collected on both days 15 and 29 were immunohistochemically (IHC) stained for protein products of stemness genes. 
Staining results of Neu, SOX9, c-myc and WNT3 were evaluated and expressed as positive cells in 10 high-power (200x) fields.P values 
for comparison between groups are shown (D). Day 15 tumors (n=2 per group) were digested to test intratumoral BCSCs/iBCSCs using 
mammosphere formation assays. The experiments were performed in duplicate and the means ± SD are shown. *** indicates P<0.001 (E). 
Day 29 tumors (n=5 per group) were digested for analysis of intratumoral BCSCs/iBCSCs using the same method as described above. The 
experiments were performed in duplicate and the means ± SD are shown. *** indicates P<0.001 (F). Oncotarget 3748 www.impactjournals.com/oncotarget
These data strongly suggest increased apoptosis in BC 
cells exposed to this combinatorial treatment vs. DSF/Cu 
alone (Supplementary Fig. S2).
DSF/Cu blocked the IR-induced stemness via 
downregulation  of  the  NF-κB-stemness  gene 
pathway in vitro
As DSF/Cu has been shown to be an effective 
proteasome inhibitor, that can result in inhibition of NF-
κB activity [21, 27]. We determined that DSF/Cu was able 
to markedly inhibit IR-induced upregulation of NF-κB 
(Supplementary Fig. S3). Studies have also shown that 
NF-κB plays a major role in regulating the expression of 
the stemness genes ERBB2 [4], SOX9 [29], MYC [30], 
and WNT [31]. In this regard, we found potential NF-κB 
binding sites in the promoter regions of WNT3 for human 
and mouse (Supplementary Table S1). However, the role 
of NF-κB in determining stem cell fates of irradiated BC 
cells has never been investigated. Using two human and 
one mouse BC cell lines, we detected significant increases 
in vitro of stemness gene expression of ERBB2, SOX9, 
and MYC at the mRNA and protein levels in irradiated 
cells (Fig. 2A, B and Supplementary Table S2). In vitro 
treatment of irradiated cells with DSF/Cu reduced the 
expression of these stemness genes at the mRNA as well 
as protein levels (Fig. 2A, B and Supplementary Table S2). 
Additionally, we showed that the inhibitory effect of DSF/
Cu on stemness gene expression was NF-κB dependent, as 
treatment with either the NF-κB inhibitor(NF-κBi) IMD-
0354 or siRNA knockdown of NF-κB (p65) expression 
displayed similar stemness inhibition as measured by 
gene expression and mammosphere formation (Fig. 2A-
C). In contrast, treatment with the ROS inhibitor (ROSi) 
N-Acetyl-L-cysteine (NAC) did not. ROS did not seem 
to play a role in modulating the NF-κB- stemness gene 
pathway, since the ROS inhibitor did not impact the ability 
of either DSF/Cu, IMD-0354 or the NF-κB p65 siRNA to 
inhibit the expression of stemness genes (Fig. 2A, B). 
DSF blocked IR-induced stemness in vivo resulting 
in inhibition of both primary tumor growth and 
spontaneous lung metastasis
To determine the impact of IR on stemness 
in primary breast tumors, and whether DSF/Cu can 
counteract IR-induced stemness in vivo, we used the 4T1 
cell line-derived syngeneic BALB/c mouse tumor model, 
which closely resembles human breast cancer and forms 
spontaneous lung metastases [32]. Consistent with our in 
vitro findings (Fig. 2A, B), IR increased stemness genes 
ERBB2, SOX9, and MYC and WNT3 mRNA (1.21-4.52 
fold) and protein expression (Fig. 3B-D, Supplementary 
Table S3). Additionally, the number of mammospheres 
formed from tumors obtained from IR-treated mice was 
higher than the number obtained from tumors of mice 
treated with vehicle, as measured using tumors obtained 
from these groups of mice one day after the treatment was 
completed (day 15) and at the end of the experiment (day 
29). The increase at day 15 was 61.0%, and at day 29, it 
was 84.2% (Fig. 3E, F). Although IR yielded a modest 
reduction in primary tumor volume compared to the 
vehicle control (20.1%) (Fig. 3A), strikingly, the high level 
of IR-induced stemness correlated with a 51.7% greater 
nodular area of spontaneous lung metastases compared 
to the vehicle control (Fig. 4A). However, we found that 
the combination of IR and DSF was significantly more 
effective at suppressing primary tumor growth compared 
to IR alone (74.2%), DSF alone (71.1%) or vehicle (79.4% 
) treated mice on day 29 (Fig. 3A). It should be noted that 
in contrast to in vitro experiments, that because a high 
level of endogenous Cu2+ exists in tumor environments, 
exogenous Cu2+ was not needed in these in vivo-based 
Figure 4: IR+DSF shows potent inhibition of 
spontaneous lung metastasis counteracting the 
incremental effect of IR. As described in Fig. 3, at the time 
of sacrifice (on day 29), lungs were harvested from the mice 
(n=5  per  group)  and  formalin-fixed,  paraffin-embedded  lung 
tissues  were  H&E  stained.  Representative  images  are  shown 
at a 200x magnification. The areas of spontaneous pulmonary 
metastatic  nodules  in  each  section  were  quantified  from  10 
randomly  selected  high-power  200x  fields.  Means  ±  SD  are 
shown. *** indicates P<0.001 and *indicates P<0.05(A). Whole 
body weight of each mouse, a marker for toxicity, was measured 
twice per week. Means ± SD are shown (B).Oncotarget 3749 www.impactjournals.com/oncotarget
experiments  for  DSF  efficacy  [21,  33].  The  higher 
potency anti-tumor effect of the combinatorial therapy 
of the mice was associated with a marked reduction of 
stemness gene expression and mammosphere formation 
in primary tumors compared to that of mice treated with 
either IR or DSF alone or vehicle (Fig. 3B-F). On day 
15, the combination of IR and DSF already resulted in a 
reduction of stemness mRNA expression (4.13-6.25 fold) 
and mammospheres (87.2%) compared to tumors treated 
with IR alone (Fig. 3B, D, E, Supplementary Table S3). 
This effect was sustained until day 29, when the tumor 
diameter of control mice reached the upper allowable 
limit of 1.5 cm (Fig. 3C, D, F, Supplementary Table S3). 
The decreased expression of stemness genes (1.92-5.25 
fold) was directly related to the functional properties of 
BCSCs, as noted by the markedly reduced ability of the 
treated tumor cells to form mammospheres (87.2%) (Fig. 
3C, D, F, Supplementary Table S3). Relative to mice 
treated with vehicle, DSF-treated non-irradiated mice 
also exhibited a reduction of stemness gene expression 
(1.88-6.24 fold on day 15; 0-2.73 fold on day 29) and 
decreased mammosphere formation (60.2% on day 15; 
64.8% on day 29) (Fig. 3B-F and Supplementary Table 
S3). Clearly, the combination of IR and DSF eliminated 
the majority of BCSCs/iBCSCs in vivo. Consequently, the 
size of spontaneous lung metastatic nodules was reduced 
89.6% in DSF-treated irradiated mice and 20.4% in DSF 
treated non-irradiated mice, compared to mice treated with 
vehicle (Fig. 4A). In sharp contrast, as previously noted, 
there was a 51.7% increase in the size of spontaneous lung 
metastatic nodules in irradiated mice compared to mice 
treated with vehicle (Fig. 4A). Toxicity was not observed 
in the mice enrolled in this study using body weight as an 
indicator of drug-induced toxicity (Fig. 4B) [34].
DISCUSSION
RT uses high-energy radiation to kill cancer cells 
and shrink tumors and is one of the major treatments for 
breast cancer and other types of cancer with curative or 
palliative intent [35]. However, radioresistant pre-existing 
BCSCs, and as our paper describes, the presence of 
radiation-induced BCSCs are challenging for a beneficial 
outcome of RT as BCSCs are the root of cancer initiation, 
progression, and metastasis [36, 37]. In an effort to 
significantly improve the efficacy of RT for breast cancer, 
we investigated and identified a way to target radioresistant 
pre-existing BCSCs and block the formation of radiation 
induced BCSCs with DSF/Cu. Our study shown here not 
only confirmed independently the finding of radiation 
induces BCSCs, first reported by F Pajonk’s group [6], but 
also identified the role of the NF-κB-mediated stemness 
gene pathway in the generation of IR-induced stem cells 
from nonstem BC cells. In addition, we found that IR had 
only a modest effect on controlling primary tumor growth 
at the same time promoting spontaneous lung metastasis 
in a syngeneic mouse model system. This surprising 
and provocative finding was confirmed repeatedly in in 
vivo experiments using the same mouse model (Fig. 4A, 
B and data not shown). The significant increase in lung 
metastasis in IR treated mice compared to vehicle treated 
mice is likely attributed to IR-induced stemness (Fig. 3B-
F). Nevertheless, it is noteworthy that the inhibition of 
primary tumor growth may also be a contributing factor 
to significant decrease in lung metastasis in IR and DSF 
treated mice compared to those treated with either IR or 
DSF alone (Fig. 3A, Fig. 4A). When comparing IR and 
DSF with DSF alone, it was shown that the products of the 
four stemness genes at the mRNA level in day 15 tumors 
were comparable in both groups but markedly reduced 
compared to those detected in tumors of mice treated 
with IR. However, in day 29 tumors, mRNA expression 
of c-myc and WNT3 were reduced in both groups of mice 
relative to the IR group, but ERBB2 and SOX9 mRNA 
levels were significantly reduced only in the tumors of 
mice treated with IR and DSF (Fig.3B, C). Of the four 
stemness gene products analyzed in day 15 and 29 tumors 
at the protein level, the expression of SOX-9 and c-myc, 
but not ERBB2 and WNT3, was significantly lower in 
the mice treated with the IR and DSF than DSF alone. 
Furthermore, the number of mammospheres of tumors 
treated with IR and DSF, however, was significantly lower 
than that of tumors treated with DSF alone (Fig. 3E, F). 
Therefore, it seems that SOX9 and c-myc might play more 
dominant roles than ERBB2 and WNT3 in determining 
tumor stemness in this tumor model. 
Through investigation of the mechanism underling 
the inhibition of stemness gene expression, we found 
that DSF/Cu and NF-κB inhibitors, which both result in 
a blockade of NF-κB signaling, prevented the formation 
of iBCSCs. The downregulation of NF-κB signaling by 
DSF/Cu or the NF-κB inhibitor or NF-κB p65 siRNA 
knockdown significantly blocked IR-induced expression 
of stemness genes ERBB2, SOX9, MYC and WNT3 (Fig. 
2A, B). As a result of these events, markedly decreased 
or depleted BCSCs/iBCSCs were detected using in vitro 
and in vivo-based assays, namely ALDH activity as a 
marker (Fig. 1A), mammosphere formation (Fig. 1B, D, 
Fig. 2C ), tumorigenicity in vivo (Fig. 1C) , mammosphere 
formation of digested primary tumor cells (Fig. 3E, F) and 
spontaneous lung metastasis (Fig. 4A). The information 
from our study contributes to our understanding of the 
bidirectional conversion between iBCSCs and nonstem 
BC cells and introduces the novel concept of blocking 
the formation of iBCSCs as a result of IR. Although we 
focused  only  on  the  NF-κB-  stemness  gene  pathway 
involving stemness genes ERBB2, SOX9, and MYC and 
WNT3 in our present study, we suspect other stemness 
genes or pathways may be involved as well in the process 
of IR-induced stemness [6, 11]. It will be well worth 
pursuing studies on this aspect of the BCSCs/iBCSCs 
challenge to RT. Oncotarget 3750 www.impactjournals.com/oncotarget
RT plays a significant role in the management of 
early stage, locoregionally advanced, and metastatic breast 
cancer [38]. The combinatorial approach of RT with DSF/
Cu, in which Cu2+ is endogenously present in tumors, we 
have described here provides a means to not only induce 
apoptosis of radioresistant pre-existing BCSCs, but also 
prevent the conversion of nonstem BC cells into radiation-
induced BCSCs. It is worth noting that although addition 
of Cu2+ to DSF is definitely needed for in vitro depletion 
of BCSCs/iBCSCs (Fig. 1A, B, D) [27], exogenous copper 
should not be administered in conjunction with clinical use 
of DSF given the fact that many tumors including breast 
cancer tissues contain high levels of copper compared 
to normal tissues [39-44]  and  the  beneficial  effect  of 
the copper depleting agent tetrathiomolybdate (TM) on 
reducing relapse in breast cancer patients[45]. Indeed, our 
in vivo data confirmed that exogenous copper gluconate 
administered orally (1mg/kg /day) with DSF(50 mg/kg/
day) and IR (20Gy, once) was significantly less effective 
than DSF and IR without copper gluconate in inhibiting 
primary tumor growth and lung metastasis in the 4T1 
mouse model system (data not shown). Therefore, one 
should be cautious on designing a clinical trial for cancer 
treatment using DSF and copper together. 
In summary, our study offers a solid foundation 
for an immediate and practicable strategy of increasing 
the efficacy and curability of radiation therapy for breast 
cancer patients using a long established, safe and low 
cost drug DSF. Moreover, our study i) introduces the 
novel concept of blocking iBCSCs through targeting the 
NF-κB-stemness gene pathway, ii) reports the finding 
that IR, delivered locally to the primary mammary 
tumors, promotes distant lung metastasis in mice, and iii) 
contributes to a paradigm shift in understanding of the 
importance of targeting CSCs and blocking the formation 
of radiation induced CSCs in RT of cancers, and therefore 
leading to the next generation of radiotherapy. 
MATERIALS AND METHODS 
Cell culture 
The human BC cell lines MDA-MB-231, MDA-
MB-231-luc-D3H1,  SUM149,  UACC-812  and  mouse 
BC cell line 4T1 were cultured in RPMI 1640 medium 
(Mediatech) supplemented with 2 mmol/L L-glutamine 
(Mediatech) and 10% fetal calf serum (FCS; Atlanta 
Biologicals). This cell culture medium is referred to as 
complete medium. Normal human mammary epithelial 
cells were purchased from Lifeline Cell Technology and 
cultured using MammaryLife Medium Complete Kit 
(Lifeline Cell Technology). All cells were cultured at 37°C 
in a 5% CO2 atmosphere. MDA-MB-231 and SUM149 
cell lines were acquired from the Duke Comprehensive 
Cancer Center Cell Culture Facility. UACC-812 and 4T1 
cell lines were purchased from the American Type Culture 
Collection (ATCC). The MDA-MB-231-luc-D3H1 cell 
line was obtained from Xenogen Corporation. 
Chemical reagents and antibodies 
Tetraethylthiuram  disulfide  (disulfiram,  DSF), 
Copper Chloride or Copper(II) D-gluconate (Cu), NF-
κB inhibitor IMD-0354, and ROS inhibitor NAC were 
purchased from Sigma-Aldrich. DSF and IMD-0354 were 
reconstituted in DMSO for all in vitro experiments. DSF 
was reconstituted in olive oil for in vivo experiments. 
Cu was reconstituted in distilled water and NAC was 
reconstituted in RPMI 1640 medium for all experiments. 
Antibodies for Western blotting: human and mouse 
HER2/ERBB2 (#2242) (1:1000 dilution)-, human and 
mouse c-myc (#9402) (1:1000 dilution)-, human cleaved 
PARP (#9541) (1:1000 dilution), human phosphorylated 
(p)-p38 MAPK (#9211) (1:1000 dilution)-, human p38 
MAPK (#9212) (1:1000 dilution)-, human p-AKT (#9271) 
(1:1000 dilution), human AKT (#4685) (1:1000 dilution), 
and human and mouse β-actin (#4970) (1:2000 dilution)-
specific rabbit monoclonal antibodies (mAbs) and goat 
anti-rabbit IgG, HRP-linked antibody (#7074) (1:2000) 
were purchased from Cell Signaling Technology. Human 
and mouse SOX9-specific rabbit antibody (Ab) (ab26414) 
(1μg/mL)  was  purchased  from Abcam. All  antibodies 
were diluted in Tris Buffered Saline with 0.1% Tween® 
20 (TBST) containing 5% nonfat dry milk plus 2% 
bovine serum albumin (BSA). All dilutions were prepared 
immediately before use.
Antibodies for IHC staining: mouse Neu-specific 
rabbit Ab (#sc-284) (1:250 dilution) and mouse SOX9-
specific  rabbit  Ab  (#sc-20095)  (1:200  dilution)  were 
purchased from Santa Cruz Biotechnology. Mouse 
c-myc-specific  rabbit  mAb  (#9402)  (1:500  dilution) 
was purchased from Cell Signaling Technology. Mouse 
WNT3-specific  rabbit  Ab  (#ab32249)  (1μg/mL)  was 
purchased from Abcam. All antibodies were diluted in 
TBST containing 5% normal horse serum and 1% BSA. 
All dilutions were prepared immediately before use. 
D-Luciferin Firefly, potassium salt was purchased from 
Xenogen. The Dual-Glo™ Luciferase Assay System, 
pGL4.32[luc2P/NF-κB-RE/Hygro]vector, and pRL-SV40 
vector were purchased from Promega. 
Animals
Six week old NOD/SCID female mice were 
purchased from Taconic and 6 week old BALB/c female 
mice were purchased from the Massachusetts General 
Hospital COX7 animal facility. All the animal studies have 
been approved by the Institutional Animal Care and Use 
Committee.Oncotarget 3751 www.impactjournals.com/oncotarget
Flow cytometry and cell sorting
Cells were collected and were then incubated with 
ALDEFLUOR® reagent (Stem Cell Technologies), with 
or without the ALDH inhibitor DEAB according to the 
manufacturer’s instructions. ALDHneg cells were sorted 
using a BD Biosciences FACSAria II cell sorter.
Irradiation (IR)
In vitro fractionated IR was performed on cells 
plated in 6-well plates at a density of 2x105 cells/ well 
in 2 mL of complete medium at 3.75Gy daily for 5 days 
unless otherwise specified. In vitro a single dose of IR was 
performed on cells plated in 6-well plates at a density of 
2x105 cells/ well in 2 mL of complete medium at 10Gy. In 
vivo, a single dose of 20Gy was delivered locally to each 
mouse tumor. The Mark I Model 30 Cesium Irradiator (JL 
Shepherd and Associates) was used for all IR experiments 
in this study.
Mammosphere formation 
Cells were plated in 6-well plates at a density 
of 2x105 cells/ well in 2 mL of complete medium and 
received fractionated irradiation. Twenty-four hours after 
irradiation, cells were treated with DSF/Cu (2.5 µM/1 µM) 
or 1 µM NF-κB inhibitor IMD0354 for an additional 24 
hours. Mammosphere formation was performed by seeding 
the cells (1000 cells/ well) in a 24-well ultra-low adherent 
plate (Corning Incorporated) in 500 μL of mixed medium 
containing 32% MethoCult medium, 20% MammoCult 
basal human medium with a final concentration of 2% 
MammoCult  proliferation  supplements  (STEMCELL 
Technologies), and 48% DMEM supplemented with final 
concentrations of 100 pg/mL EGF, 50 ng/mL bFGF, 5 ng/
mL stem cell factor, 1x10-6 M hydrocortisone, and 5 μg/mL 
insulin. The cells were cultured at 37°C in a 5% O2 and 5% 
CO2 humidified atmosphere for 14 days. Mammosphere 
pictures were taken using a Zeiss Inverted Fluorescence 
Microscope on day 10 or 14. Numbers of mammosphere 
were count on day 14. Mammosphere formation was also 
performed by seeding (1000 cells/ well) in a 24-well ultra-
low adherent plate of the Fluorescence Activated Cell 
Sorting (FACS) sorted ALDHneg cells or cells from a single 
cell suspension collected from a disaggregated tumor. 
Transfection with siRNA
MDA-MB-231 and SUM149 cells were plated in 
12-well plates at a density of 4x104 cells/ well and 3.2x104 
cells/ well in 0.5mL of complete medium, respectively. 
Cells were transfected with 100 nmol Signalsilence NF-
κB p65 siRNA (#6261; Cell signaling Technology) using 
the X-tremeGENE siRNA Transfection Reagent (Roche) 
following the manufacturer’s instructions. SignalSilence 
Control siRNA (#6201; Cell Signaling technology) was 
used as a control. Cells were then incubated for 48 hours 
before initiating specified treatments.
Western blotting analysis 
Cells were plated in 6-well plates at a density of 
2x105 cells/ well in 2 mL of complete medium and were 
treated as indicated. Cells were collected and lysed in 
lysis buffer (10 mM Tris–HCl (pH 8.2), 1% NP40, 1 
mM EDTA, 0.1% BSA, 150 mM NaCl) containing 1/50 
(vol/vol) of a protease inhibitor cocktail (Calbiochem), 
or proteins were extracted from frozen mouse tumors by 
homogenization in the presence of 1 mL of lysis buffer. 
Western blotting for signaling-related proteins and proteins 
of stemness genes was carried out as described [46]. The 
investigators who analyzed the samples from the tumors 
were blinded to the type of treatment received by the mice.
Cell proliferation and MTT assay
Cells were plated in triplicate in 96-well plates at 
a density of 2.5x103 cells/ well in 100 uL of complete 
medium and were treated as indicated. Cell proliferation 
was evaluated by an MTT assay at the indicated time 
point. MTT assays were carried out as described [46]. 
Real-Time qRT-PCR 
Cells were plated in 6-well plates at a density 
of 2x105 cells/ well in 2 mL of complete medium and 
were treated as indicated. Total RNA from all in vitro 
experimental samples or frozen mouse tumors was 
isolated using TRIzol (Life Technologies), and was 
reverse transcribed using M-MLV reverse transcriptase 
(Life  Technologies)  according  to  the  manufacturer’s 
instructions. All samples within each experiment were 
reverse transcribed at the same time. The resulting cDNA 
was diluted to a concentration of 100 ng/mL in nuclease-
free water and was stored in aliquots at –20°C until use. 
Real-time qPCR using cDNA as a template with SYBR 
green detection was performed using a LightCycler 96 
system (Roche) with FastStart SYBR Green Master 
Mix (Roche) and primers for each gene as shown in 
Supplementary Table S4. Appropriate no-RT and non-
template controls were included in each 96-well PCR 
reaction, and dissociation analysis was performed at the 
end of each run to confirm the specificity of the reaction. 
Each gene expression level was normalized to mRNA 
levels of the housekeeping gene r18S. Fold changes 
of each gene’s expression was compared to that of the 
untreated sample using the 2(-Delta Delta C(T)) method Oncotarget 3752 www.impactjournals.com/oncotarget
[47].
Dual-Glo luciferase assay
MDA-MB-231 cells were plated in 12-well plates 
at a density of 4x104 cells/ well in 0.5 mL of complete 
medium and cultured for 24 hours, the pGL4.32[luc2P/
NF-κB-RE/Hygro]  and  pRL-SV40  vectors  were  co-
transfected into adherent cells. After 24 hours, the 
transfected cells were irradiated with a single dose of 10 
Gy and were then treated with DSF/Cu (2.5 µM/1 µM) 
or 1 µM IMD-0354 for 24 hours. A dual luciferase assay 
was then performed with these cells using the Dual-
Glo luciferase assay kit according to the manufacturer’s 
instructions.  NF-κB  luciferase  activity,  normalized  to 
Renilla luciferase activity, was expressed relative to that 
of the untreated cells, which was set at 1.0. 
In vivo tumorigenicity assay
In vitro, MDA-MB-231-luc-D3H1 cells were 
fraction-irradiated at 3.75 Gy/day for 5 days and were 
cultured for 24 hours followed by an additional 24 hours 
with or without the treatment of DSF/Cu (2.5 µM/1 µM). 
Three groups of NOD/SCID mice (n=4) were injected 
i.p. with either untreated MDA-MB-231-luc-D3H1 cells, 
irradiated MDA-MB-231-luc-D3H1 cells treated with 
DSF/Cu, or only irradiated MDA-MB-231-luc-D3H1 
cells. The same number of cells was used for each group, 
with 2x106 cells in 25 μL RPMI 1640 and 25 μL Matrigel 
injected i.p. in each mouse. Tumorigenicity measured as 
tumor growth was monitored in each mouse every 3-4 
days by bioluminescence image (BLI) and tumor burden 
quantitated as photons/second. 
In vivo syngeneic tumor model 
Mouse BC 4T1 cells (5x105 cells/mouse) were 
implanted subcutaneously in the thigh of right hind leg 
of BLAB/c mice. Body weight and tumor volume were 
measured twice per week. Tumor volume was measured 
by digital calipers. Treatments were initiated on day 
7 when the tumor developed and had an approximate 
diameter of 5 mm. Mice were divided into 4 groups (n=7) 
using a stratified randomization strategy, such that the 
difference of mean tumor volumes was not statistically 
significant between each group (P>0.5). Mice in group 1 
were treated with olive oil (vehicle control, 200 µL) orally 
from day 7 to day 14. Mice in group 2 were treated with a 
20Gy irradiation on day 10. Mice in group 3 were treated 
with oral administration of DSF (50 mg/kg/day) from day 
7 to day 14. Mice in group 4 were treated with a 20Gy 
irradiation on day 10 and oral administration of DSF (50 
mg/kg/day) from day 7 to day 14. All oral administration 
was given by an oral gavage using an 18 gauge plastic 
feeding tube (Solomon Scientific). When tumor diameters 
from untreated mice reached 1.5 cm, all mice were 
sacrificed. Primary tumors and lungs were collected for 
further analysis. 
Samples preparations from primary mouse 
tumors 
For mammosphere formation assay: a non-necrotic 
primary tumor tissue specimen from each mouse was 
collected at the time of sacrifice, minced into 3x3 mm 
pieces and digested with Collagenase IV (1mg/mL PBS)
(Worthington Biochemical Corp.) at 37°C for 1 hour. 
A single cell suspension was obtained by filtering the 
digested tumor through a 40μM cell strainer. 
For total RNA and protein extractions: a non-
necrotic primary tumor tissue specimen from each mouse 
was collected at the time of sacrifice, minced (3x3 mm) 
and stored at -80°C for total RNA or protein extraction. 
For IHC staining: the remaining non-necrotic tumor 
tissue specimen from each mouse was collected at the time 
of sacrifice and formalin-fixed and paraffin-embedded 
(FFPE). FFPE blocks were sectioned using MICROM 
HM325 Rotary Microtome (Thermo Fisher Scientific Inc).
Analysis of areas of lung metastasis
At the time of sacrifice, mouse lungs were collected 
as described above for histological analysis of lung 
metastasis.  Four  micron-thick  formalin-fixed  paraffin-
embedded (FFPE) sections of mouse lung tissue from 
treated BALB/c mice bearing 4T1 cell tumors were stained 
with Mayer’s Hematoxylin (Sigma-Aldrich) and Eosin Y 
solution (Sigma-Aldrich) according to the manufacturer’s 
instructions. The areas of the metastatic nodules in 10 
randomly selected high-power fields (200x magnification) 
per section were measured and calculated by the SPOT 
Advanced Imaging software (Diagnostic Instruments). 
The research fellow who analyzed the lungs was blinded 
to the type of treatment received by the mice. 
IHC staining
Four micron-thick tissue sections were 
deparaffinized  and  subjected  to  antigen  retrieval. 
Following incubation with blocking buffer, slides were 
incubated with anti-Neu, -SOX9, -c-myc, and -WNT3 
Abs overnight. Sections were then rinsed with TBST, 
followed by 45-minute incubation with the EnVision™+ 
Dual Link System-HRP goat anti-rabbit Ig (Dako). The 
detection of staining signals was performed with the DAB 
Peroxidase Substrate Kit from Dako, and the sections 
were counterstained with hematoxylin. Staining results of Oncotarget 3753 www.impactjournals.com/oncotarget
stemness gene protein were analyzed by two investigators 
who were blinded to the type of treatment received by 
the mice, by counting the positive cells in 10 randomly 
selected high-power (200x) fields. Complete membrane 
staining was considered as positive for Neu expression; 
nuclear staining was considered as positive for SOX9 
and c-myc expression, and cell membrane and cytoplasm 
staining were considered as positive for WNT3 expression. 
Statistical analysis 
For  in vivo tumor volumes, estimation of the 
treatment group specific mean responses over time and 
their comparisons were performed by using longitudinal 
general linear mixed effects model with compound 
symmetry error covariance structure. The subject level 
intercepts were random, and both time effect and time 
x treatments interactions were considered fixed effects. 
The longitudinal treatment effects were compared by 
comparing the treatment specific slopes by linear contrast. 
For all other data analysis, averages, standard deviations, 
and unpaired t-tests were calculated using Microsoft 
Excel. In vitro data shown represent the mean ± SD of the 
results obtained in at least three independent experiments. 
In vivo data shown represent the mean ± SD of the results 
obtained in each group. Differences between groups were 
considered significant when the P value was < 0.05.
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